Evidence map›Paper›PMID 27806715›Full record

ArticleBMC cancer2016

Prognostic contribution of mammographic breast density and HER2 overexpression to the Nottingham Prognostic Index in patients with invasive breast cancer.

Amro Masarwah, Päivi Auvinen, Mazen Sudah, Vaiva Dabravolskaite, Otso Arponen, Anna Sutela, Sanna Oikari, Veli-Matti Kosma, Ritva Vanninen

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Amro MasarwahDepartment of Clinical Radiology, Kuopio University Hospital, Puijonlaaksontie 2, 70210, Kuopio, PO Box PL 100, 70029, KYS, Finland. amro.masarwah@kuh.fi.ORCID 0000-0001-9687-6020
Päivi AuvinenDepartment of Oncology, Kuopio University Hospital, Puijonlaaksontie 2, 70210, Kuopio, PO Box PL 100, 70029, KYS, Finland.
Mazen SudahDepartment of Clinical Radiology, Kuopio University Hospital, Puijonlaaksontie 2, 70210, Kuopio, PO Box PL 100, 70029, KYS, Finland.
Vaiva DabravolskaiteInstitute of Clinical Medicine, Internal Medicine, University of Eastern Finland, Yliopistonranta 1E, P.O.Box 1627, 70211, Kuopio, Finland.
Otso ArponenDepartment of Clinical Radiology, Kuopio University Hospital, Puijonlaaksontie 2, 70210, Kuopio, PO Box PL 100, 70029, KYS, Finland.
Anna SutelaDepartment of Clinical Radiology, Kuopio University Hospital, Puijonlaaksontie 2, 70210, Kuopio, PO Box PL 100, 70029, KYS, Finland.
Sanna OikariInstitute of Biomedicine, Department of Medicine, University of Eastern Finland, Yliopistonranta 1E, P.O.Box 1627, 70211, Kuopio, Finland.
Veli-Matti KosmaDepartment of Pathology, Kuopio University Hospital, Puijonlaaksontie 2, 70210, Kuopio, PO Box PL 100, 70029, KYS, Finland.
Ritva VanninenDepartment of Clinical Radiology, Kuopio University Hospital, Puijonlaaksontie 2, 70210, Kuopio, PO Box PL 100, 70029, KYS, Finland.
University of Eastern Finland · FIKuopio University Hospital · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo investigate whether very low mammographic breast density (VLD), HER2, and hormone receptor status holds any prognostic significance within the different prognostic categories of the widely used Nottingham Prognostic Index (NPI). We also aimed to see whether these factors could be incorporated into the NPI in an effort to enhance its performance.

methodsThis study included 270 patients with newly diagnosed invasive breast cancer. Patients with mammographic breast density of <10 % were considered as VLD. In this study, we compared the performance of NPI with and without VLD, HER2, ER and PR. Cox multivariate analysis, time-dependent receiver operating characteristic curve (tdROC), concordance index (c-index) and prediction error (0.632+ bootstrap estimator) were used to derive an updated version of NPI.

resultsBoth mammographic breast density (VLD) (p < 0.001) and HER2 status (p = 0.049) had a clinically significant effect on the disease free survival of patients in the intermediate and high risk groups of the original NPI classification. The incorporation of both factors (VLD and HER2 status) into the NPI provided improved patient outcome stratification by decreasing the percentage of patients in the intermediate prognostic groups, moving a substantial percentage towards the low and high risk prognostic groups.

conclusionsVery low density (VLD) and HER2 positivity were prognostically significant factors independent of the NPI. Furthermore, the incorporation of VLD and HER2 to the NPI served to enhance its accuracy, thus offering a readily available and more accurate method for the evaluation of patient prognosis.

Indexed as

Biomarkers, TumorBreast DensityGene ExpressionAdultAgedAged, 80 and overBreast NeoplasmsCombined Modality TherapyErb-b2 Receptor Tyrosine KinasesFemaleHumansMiddle AgedNeoplasm GradingNeoplasm StagingPrognosisProportional Hazards ModelsBiomarkers, TumorErb-b2 Receptor Tyrosine KinasesBreast densityHER2Nottingham prognostic indexNPIPredictionPrognosis

Identifiers

PMID27806715
PMCPMC5094093
OpenAlexW2548200984

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.